These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 30485867)
21. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients. Sasaki T; Yasui-Furukori N; Komahashi-Sasaki H; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K Basic Clin Pharmacol Toxicol; 2021 May; 128(5):677-685. PubMed ID: 33470005 [TBL] [Abstract][Full Text] [Related]
22. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study). Lloret-Linares C; Daali Y; Chevret S; Nieto I; Molière F; Courtet P; Galtier F; Richieri RM; Morange S; Llorca PM; El-Hage W; Desmidt T; Haesebaert F; Vignaud P; Holtzmann J; Cracowski JL; Leboyer M; Yrondi A; Calvas F; Yon L; Le Corvoisier P; Doumy O; Heron K; Montange D; Davani S; Déglon J; Besson M; Desmeules J; Haffen E; Bellivier F BMC Pharmacol Toxicol; 2017 Nov; 18(1):70. PubMed ID: 29115994 [TBL] [Abstract][Full Text] [Related]
23. Venlafaxine pharmacogenetics: a comprehensive review. Suwała J; Machowska M; Wiela-Hojeńska A Pharmacogenomics; 2019 Jul; 20(11):829-845. PubMed ID: 31368838 [TBL] [Abstract][Full Text] [Related]
24. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. Nassan M; Nicholson WT; Elliott MA; Rohrer Vitek CR; Black JL; Frye MA Mayo Clin Proc; 2016 Jul; 91(7):897-907. PubMed ID: 27289413 [TBL] [Abstract][Full Text] [Related]
26. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion. Güzey C; Norström A; Spigset O Ther Drug Monit; 2002 Jun; 24(3):436-7. PubMed ID: 12021638 [TBL] [Abstract][Full Text] [Related]
27. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood. Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145 [TBL] [Abstract][Full Text] [Related]
28. Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression. Hole K; Arnestad M; Molden E; Haslemo T J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):281-285. PubMed ID: 33905640 [TBL] [Abstract][Full Text] [Related]
29. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis. Li X; Zhu L; Su Y; Fang S PLoS One; 2017; 12(10):e0185865. PubMed ID: 28982121 [TBL] [Abstract][Full Text] [Related]
30. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. Ciusani E; Zullino DF; Eap CB; Brawand-Amey M; Brocard M; Baumann P J Psychopharmacol; 2004 Dec; 18(4):559-66. PubMed ID: 15582923 [TBL] [Abstract][Full Text] [Related]
31. Alternative venlafaxine kinetics in overdose. Langford NJ; Martin U; Ruprah M; Ferner RE J Clin Pharm Ther; 2002 Dec; 27(6):465-7. PubMed ID: 12472987 [TBL] [Abstract][Full Text] [Related]
32. Precision dosing of venlafaxine during pregnancy: a pharmacokinetics modelling approach. Alenezi M; Badhan RKS J Pharm Pharmacol; 2024 Jan; 76(2):122-137. PubMed ID: 38142123 [TBL] [Abstract][Full Text] [Related]
33. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106 [TBL] [Abstract][Full Text] [Related]
34. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553 [TBL] [Abstract][Full Text] [Related]
35. CYP2D6 phenotypes and Parkinson's disease risk: a meta-analysis. Lu Y; Peng Q; Zeng Z; Wang J; Deng Y; Xie L; Mo C; Zeng J; Qin X; Li S J Neurol Sci; 2014 Jan; 336(1-2):161-8. PubMed ID: 24211060 [TBL] [Abstract][Full Text] [Related]
36. Zhou H; Yang L; Wang C; Li Z; Ouyang Z; Shan M; Gu J; Wei Y Drug Metab Dispos; 2019 Dec; 47(12):1425-1432. PubMed ID: 31658948 [TBL] [Abstract][Full Text] [Related]
37. An observational study of Venlafaxine and CYP2D6 in clinical practice. Rolla R; Gramaglia C; Dalò V; Ressico F; Prosperini P; Vidali M; Meola S; Pollarolo P; Bellomo G; Torre E; Zeppegno P Clin Lab; 2014; 60(2):225-31. PubMed ID: 24660534 [TBL] [Abstract][Full Text] [Related]
38. Recurrence of Serotonin Toxicity and Influence of Cytochrome 2D6 Polymorphism. Volon B; Willemart T; Haufroid V; Hantson P Prim Care Companion CNS Disord; 2019 Nov; 21(6):. PubMed ID: 31794166 [No Abstract] [Full Text] [Related]
39. Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients. Godoy AL; Rocha A; da Silva Souza C; Lanchote VL J Clin Pharmacol; 2016 May; 56(5):567-75. PubMed ID: 26331791 [TBL] [Abstract][Full Text] [Related]
40. The Associations Between CYP2D6*10 C188T Polymorphism and Pharmacokinetics and Clinical Outcomes of Tramadol: A Systematic Review and Meta-analysis. Wen QH; Zhang Z; Cai WK; Lin XQ; He GH Pain Med; 2020 Dec; 21(12):3679-3690. PubMed ID: 32488232 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]